Core Insights - The company reported a revenue of 749 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 2.07% [1] - The net loss attributable to shareholders of the listed company was 69.23 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 72.39 million yuan [1] - The basic loss per share was 0.36 yuan [1]

山东赛托生物科技股份有限公司 证券代码：300583 证券简称：赛托生物 编号：2025-040 关于 2025 年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 （一）本次计提资产减值准备的原因 根据《企业会计准则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关规定，为真实、准确反映公司的财务状况，公司基 于谨慎性原则，对合并报表范围内截至 2025 年 9 月 30 日的存货、应收款项、固定 资产、无形资产、商誉等资产进行了全面清查和减值测试，对合并报表范围内可能 发生资产减值损失的有关资产计提相应减值准备。 （二）本次计提资产减值准备的资产范围、总金额和计入的报告期间 经公司及下属子公司对报告期末存在减值迹象的各类资产，范围包括存货、应 收款项、固定资产、无形资产、商誉等，进行全面清查和减值测试后，计提 2025 年 前三季度各项资产减值准备合计 40,591,741.96 元，具体明细如下： 单位：元 | 项 目 | 资产减值计提金额 | | --- ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥241,425,650.02, representing a year-on-year increase of 21.70%[4] - The net profit attributable to shareholders was -¥16,543,142.49, a significant decline of 1,199.98% compared to the same period last year[4] - The basic earnings per share for Q3 2025 was -¥0.08, reflecting a decrease of 900.00% year-on-year[4] - The total profit for the year-to-date was -¥75,201,207.54, a decline of 462.69% compared to the same period last year[9] - Net profit for the period was a loss of ¥79,128,524.62, compared to a profit of ¥13,200,659.89 in the previous period, indicating a significant decline[19] - Operating profit turned negative at -¥74,138,162.11, down from a positive ¥21,181,969.70 in the prior year[19] - Basic and diluted earnings per share were both -¥0.36, compared to ¥0.08 in the previous period[20] Cash Flow - The cash flow from operating activities for the year-to-date was ¥77,809,222.82, down 53.96% from the previous year[4] - The net cash flow from operating activities was $77.81 million, a decrease of 54% compared to $169.01 million in the previous period[22] - Cash inflow from operating activities totaled ¥553,336,844.67, down from ¥607,886,012.30, a decrease of approximately 8.9% year-over-year[21] - Cash outflows from operating activities totaled $475.53 million, compared to $438.87 million in the prior period[22] - The net cash flow from investing activities was -$27.43 million, an improvement from -$61.30 million year-over-year[22] - Cash inflows from investment activities totaled $10.52 million, significantly higher than $2.36 million in the prior period[22] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,866,079,082.42, a decrease of 5.28% from the end of the previous year[4] - Total current assets decreased from 1,284,916,162.65 CNY to 1,189,810,971.39 CNY, a decline of approximately 7.41%[14] - Total assets decreased from 3,025,806,782.53 CNY to 2,866,079,082.42 CNY, a decline of approximately 5.26%[14] - Total non-current assets decreased from 1,740,890,619.88 CNY to 1,676,268,111.03 CNY, a decline of approximately 3.71%[14] - The total liabilities decreased to ¥1,064,836,700.02 from ¥1,141,641,832.99, a reduction of approximately 6.7%[19] - Total equity attributable to shareholders decreased to ¥1,766,097,218.21 from ¥1,839,121,540.57, a decline of about 4.0%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,737[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares, with 7,440,000 shares pledged[11] - The second-largest shareholder, Mi Chaojie, holds 20.62% of shares, totaling 39,116,800 shares[11] Investment and Expenses - The company experienced a 50.40% decrease in investment income, totaling ¥5,391,355.27 for the year-to-date[8] - Research and development expenses were ¥32,249,551.03, down from ¥41,391,541.00, reflecting a reduction of about 22.1%[19] - Cash paid to employees was $83.66 million, down from $107.49 million year-over-year[22] - Cash paid for taxes was $23.87 million, a decrease from $40.83 million in the previous period[22] - Cash paid for the acquisition of fixed assets was $34.96 million, down from $63.66 million year-over-year[22] Credit and Impairment - The company reported a 514.07% increase in credit impairment losses, amounting to -¥9,637,137.21 for the year-to-date[8] - The company reported a credit impairment loss of -¥9,637,137.21, compared to a gain of ¥2,327,445.50 in the previous period[19]

Group 1 - Dongfang Caifu announced that shareholders plan to transfer a total of 237.8 million shares at a price of 24.40 yuan per share, with 32 institutional investors participating in the bidding [1] - Laofengxiang's subsidiary plans to invest 24 million USD to acquire a 20% stake in Maybach Luxury Goods Asia Pacific, becoming the second-largest shareholder [1] - Saito Bio's subsidiary received a CEP certificate for Dexamethasone Sodium Phosphate, allowing it to sell in international markets [2] Group 2 - Jianglong Shipbuilding is expected to win a bid for a 600-ton fishery enforcement vessel project worth 72.99 million yuan, accounting for 4.22% of its audited revenue for 2024 [3] - Shikong Technology is planning to acquire control of Shenzhen Jiahe Jinwei Electronic Technology Co., Ltd., with stock trading suspended for up to 5 trading days [4] - Mould Technology's controlling shareholder plans to reduce its stake by up to 1% due to funding needs [5] Group 3 - Guokong Electronics expects a net profit increase of 64.72% to 80.17% for the first three quarters of 2025, with projected revenue of 340 million to 370 million yuan [7] - Beimo High-Tech anticipates a net profit increase of 50% to 60% for the same period, with a projected net profit of 125 million to 133 million yuan [8] - ST Haofeng's controlling shareholder has transferred 15.0046% of shares to Zhixin Network at a price of 6 yuan per share, totaling 331 million yuan [9] Group 4 - ST Changyuan's major shareholder plans to reduce its stake by up to 3% within 90 days due to risk management [11] - Runze Technology's shareholder plans to reduce its stake by up to 1% due to personal funding needs [12] - Limin Co. expects a net profit increase of 649.71% to 669.25% for the first three quarters of 2025, with a projected net profit of 384 million to 394 million yuan [14] Group 5 - Kanda New Materials received a government subsidy of 10.05 million yuan, accounting for 4.08% of its latest audited net profit [15] - Keheng Co.'s shareholder plans to reduce its stake by up to 1% due to personal funding needs [16] - New Hope reported a September sales revenue of 1.746 billion yuan from 1.3942 million pigs sold, with a year-on-year decline of 23.82% [18] Group 6 - Wan'an Technology plans to invest 150 million yuan to establish a joint venture in Wuhan for automotive chassis systems [19] - Wan'an Technology also intends to acquire a 40% stake in Fuao Wan'an for 26.22 million yuan, aiming for full ownership [19] - Kuai Ke Electronics' controlling shareholder plans to transfer 4% of the company's shares through an inquiry [20] Group 7 - Changan Automobile's joint venture Avita Technology has completed payment of 3.45 billion yuan for a 10% stake in Huawei's Yiwang [21]

Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient Dexamethasone Sodium Phosphate [1] Group 1: Company Developments - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, has been granted a CEP certificate for Dexamethasone Sodium Phosphate, indicating compliance with European pharmacopoeia standards [1] - Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties [1] Group 2: Product Applications - The drug is primarily used for treating allergic and autoimmune inflammatory diseases, including connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, and acute leukemia [1] - It is also utilized in the comprehensive treatment of certain severe infections, poisoning, and malignant lymphomas [1]

Core Viewpoint - Saito Bio's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received the CEP certificate for Dexamethasone Sodium Phosphate from the European Directorate for the Quality of Medicines (EDQM), enhancing its position in the pharmaceutical market [1] Company Summary - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, applied for the CEP certificate for Dexamethasone Sodium Phosphate in April 2024 and received it in October 2025 [1] - The drug Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties, primarily used for allergic and autoimmune inflammatory diseases [1] Industry Summary - There are a total of 9 companies globally that hold valid CEP certificates for Dexamethasone Sodium Phosphate, including Shandong Sry Pharmaceutical [1]

证券代码：300583 证券简称：赛托生物 编号：2025-038 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司（以下简称"斯瑞药业"）近日收到欧洲药品质量管理局（以下简 称"EDQM"）签发的原料药欧洲药典适用性证书（以下简称"CEP 证书"），现将 相关情况公告如下： 一、原料药注册批件信息 化学原料药名称：DEXAMETHASONE SODIUM PHOSPHATE 地塞米松磷酸钠 药品生产商/持有人：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 证书编号：CEP 2025-180-Rev 00 发证机关：欧洲药品质量管理局（EDQM） 有效期：自 2025 年 10 月 1 日起五年内有效 二、原料药的相关情况 地塞米松磷酸钠是一种肾上腺皮质激素类药，具有抗炎、抗过敏、抗风湿以 及免疫抑制作用，主要用于过敏性与自身免疫性炎症性疾病，多用于结缔组织病、 活动性风湿病、类风湿性关节 ...

Group 1 - The company, Saito Bio, announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 0.1 RMB per 10 shares to all shareholders [2] - The record date for the dividend distribution is set for September 23, 2025, while the ex-dividend date is September 24, 2025 [2]

证券代码：300583 证券简称：赛托生物 公告编号：2025-037 山东赛托生物科技股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）2025 年半年度权益分 派方案已获 2025 年 9 月 12 日召开的 2025 年第一次临时股东大会审议通过，现将 权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司 2025 年第一次临时股东大会审议通过分配方案：公司以 189,702,126 股为基数，向全体股东每 10 股派发现金股利人民币 0.1 元（含税），共计派发现 金红利 1,897,021.26 元（含税），本次利润分配不送红股，不以资本公积金转增 股本，剩余未分配利润结转至以后年度分配。自董事会审议利润分配预案之日起 至实施方案的股权登记日期间，若公司股本因股权激励行权、可转债转股、股份 回购等情况发生变动，将按照分配总额不变的原则，对分配比例进行调整。 2、自分配方案披露至实施期间公司股本总数未发生变化； 二、本次实施的利润分配方案 2 ...

Core Viewpoint - The company, Saito Bio, announced the election of Ms. Li Lu as the employee representative director of the fourth board of directors during the first employee representative meeting of 2025, which will last until the end of the board's term [2]. Group 1 - The first employee representative meeting of 2025 is scheduled for September 12, 2025, at the company's administrative building [2]. - Ms. Li Lu was elected as the employee representative director of the fourth board of directors [2]. - The term for Ms. Li Lu will commence from the date of approval at the employee representative meeting until the end of the fourth board's term [2].